HOME >> BIOLOGY >> NEWS
Vaccine provides 100 percent protection against avian flu virus in animal study

PITTSBURGH, Jan. 26 University of Pittsburgh researchers announced they have genetically engineered an avian flu vaccine from the critical components of the deadly H5N1 virus that completely protected mice and chickens from infection. Avian flu has devastated bird populations in Southeast Asia and Europe and so far has killed more than 80 people.

Because this vaccine contains a live virus, it may be more immune-activating than avian flu vaccines prepared by traditional methods, say the researchers. Furthermore, because it is grown in cells, it can be produced much more quickly than traditional vaccines, making it an extremely attractive candidate for preventing the spread of the virus in domestic livestock populations and, potentially, in humans, according to the study, published in the Feb 15 issue of the Journal of Virology and made available early online.

"The results of this animal trial are very promising, not only because our vaccine completely protected animals that otherwise would have died, but also because we found that one form of the vaccine stimulates several lines of immunity against H5N1," said Andrea Gambotto, M.D., assistant professor in the departments of surgery and molecular genetics and biochemistry, University of Pittsburgh School of Medicine, and lead author of the study.

Dr. Gambotto and his colleagues constructed the vaccine by genetically engineering a common cold virus, called adenovirus, to express either all or parts of an avian influenza protein called hemagglutinin (HA) on its surface. Found on the surface of all influenza viruses, HA allows the virus to attach to the cell that is being infected and is, therefore, critical to the influenza virus' ability to cause illness and death.

Since the late 1990s, a number of outbreaks of the avian influenza H5N1 in poultry have occurred in Cambodia, China, Indonesia, Japan, Laos, South Korea, Thailand and Vietnam. Outbreaks recently have been reported in Turkey and
'"/>


26-Jan-2006


Page: 1 2 3 4 5

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine hope for sufferers of potentially fatal stomach bug
5. Vaccine to cope with viral diversity in HIV
6. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
7. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
8. Vaccine-producing plant-factories
9. HPV Vaccine: Whats next
10. Vaccine shown effective against chancroid
11. Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2020)... ... January 24, 2020 , ... The Rockies Venture Club ... to support early-stage bioscience companies in the state. , “Colorado has ... the funding they need to innovate and grow. This program will mobilize ...
(Date:1/22/2020)... ... January 21, 2020 , ... Astro ... company’s new Business Development Department. The move, which is part of the company’s ... serving as the company’s Senior Vice President where he oversaw its Cleanroom Division ...
(Date:1/7/2020)... ... January 07, 2020 , ... Lifecycle ... not just part numbers like what can be found in most catalogs, but ... and that is all linked to the impact it has on the global ...
Breaking Biology News(10 mins):
(Date:1/27/2020)... (PRWEB) , ... January 27, 2020 , ... ... advances in neuroscience and cloud and mobile computing, today announced the availability of ... across an organization to use the latest neuroscience of leadership and change research ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal ... cosmetic surgery industry at two recent North American investor forums specializing in medical ... Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in New York ...
(Date:1/10/2020)... ... January 09, 2020 , ... A new report from ... the vendor qualification process, a critical element of clinical trial set up and ... the vendor qualification process creates delays in initiation in 7% of clinical trials ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... and services, today announced the launch of its VivopureX™ recombinant mouse antibodies for ... many originally obtained from rats or hamsters, which Absolute Antibody has engineered into ...
Breaking Biology Technology:
Cached News: